Successful Treatment Using Simeprevir, Sofosbuvir and Rituximab of a Severe Form of Hepatitis C Virus-related Mixed Cryoglobulinemia with Cardiac Involvement

Numerous extrahepatic manifestations have been reported in hepatitis C virus (HCV) infection, particularly mixed cryoglobulinemia (MC). MC generally responds to clearance of HCV under pegylated-interferon plus ribavirin treatment. New direct-acting antiviral agents have been licensed for HCV under d...

Full description

Bibliographic Details
Main Authors: Rafael Mahieu, Christian Lavigne, Geoffrey Urbanski, Isabelle Fouchard Hubert, Alexandra Ducancelle, Françoise Lunel-Fabiani
Format: Article
Language:English
Published: SMC MEDIA SRL 2015-11-01
Series:European Journal of Case Reports in Internal Medicine
Subjects:
Online Access:http://ejcrim.com/index.php/EJCRIM/article/view/299
Description
Summary:Numerous extrahepatic manifestations have been reported in hepatitis C virus (HCV) infection, particularly mixed cryoglobulinemia (MC). MC generally responds to clearance of HCV under pegylated-interferon plus ribavirin treatment. New direct-acting antiviral agents have been licensed for HCV under different combinations but have not been studied in severe forms of MC. Here, we present a case report describing a life-threatening form of MC with multivisceral involvement, which was successfully treated with concomitant rituximab, sofosbuvir and simeprevir. In light of the rapid clinical remission associated with sustained virological response and the excellent side-effect profile, this treatment should be considered as a first-line therapy in severe forms of MC.
ISSN:2284-2594